Ditchcarbon
  • Customers
  1. Organizations
  2. Sarepta Therapeutics
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 10 days ago

Sarepta Therapeutics

Company website

Sarepta Therapeutics, Inc., a leading biotechnology company headquartered in the United States, is at the forefront of developing innovative genetic medicine for rare diseases, particularly Duchenne muscular dystrophy (DMD). Founded in 1980, Sarepta has achieved significant milestones, including the development of its pioneering exon-skipping therapies, which offer unique treatment options for patients with DMD. With a strong focus on advancing precision medicine, Sarepta's core products, such as eteplirsen and golodirsen, utilise cutting-edge technology to address the underlying genetic causes of muscular dystrophies. The company has established a prominent market position, recognised for its commitment to transforming the lives of patients through groundbreaking therapies. As it continues to expand its operational reach, Sarepta remains dedicated to innovation and excellence in the biotechnology industry.

DitchCarbon Score

How does Sarepta Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

27

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Sarepta Therapeutics's score of 27 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.

51%

Let us know if this data was useful to you

Sarepta Therapeutics's reported carbon emissions

In 2023, Sarepta Therapeutics reported total carbon emissions of approximately 8,428,000 kg CO2e, comprising 3,428,000 kg CO2e from Scope 1 emissions and 5,000,000 kg CO2e from Scope 2 emissions. This reflects a slight increase from 2022, when the company recorded total emissions of about 7,181,000 kg CO2e, with Scope 1 emissions at 2,701,000 kg CO2e and Scope 2 emissions at 4,789,000 kg CO2e. Sarepta Therapeutics has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives as part of their climate commitments. The company operates independently without cascading emissions data from a parent organisation, ensuring that their reported figures are solely reflective of their own operations. As a biotechnology firm headquartered in the US, Sarepta Therapeutics is positioned within an industry that increasingly prioritises sustainability and climate action, although specific commitments or pledges have not been outlined in their current reporting.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20222023
Scope 1
2,701,000
0,000,000
Scope 2
4,789,000
0,000,000
Scope 3
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Sarepta Therapeutics's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Sarepta Therapeutics is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Sarepta Therapeutics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

PYC Therapeutics Limited

AU
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

BioMarin

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Stoke Therapeutics, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Dyne Therapeutics, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Biogen

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Daiichi Sankyo

JP
•
Medical, precision and optical instruments, watches and clocks (33)
Updated 4 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250808.10
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy